India trials Ayurveda alongside standard TB treatment

A first-of-its-kind clinical study evaluating Ayurveda as an add-on to anti-TB drugs, announced on World TB Day by the Department of Biotechnology and the Ministry of Ayush.

What happened

• On World TB Day (24 March 2026), India announced what it described as the world's first clinical study to scientifically evaluate Ayurveda as an adjunct to standard Anti-Tuberculosis Treatment (ATT) — that is, given in addition to, not in place of, the proven anti-TB drug regimen.
• The study is a joint effort of the Department of Biotechnology (DBT), under the Ministry of Science & Technology, and the Ministry of Ayush, framed by Union Minister Dr Jitendra Singh as a convergence of modern biotechnology and India's traditional knowledge systems.
• It enrols about 1,250 newly diagnosed TB patients across eight institutions, including AIIMS, JIPMER and NEIGRIHMS (Shillong), and is conducted within the framework of the National TB Elimination Programme (NTEP).
• The trial is built on a DBT-Ayush Memorandum of Understanding signed on 25 May 2022, and is led on the ground by the Central Council for Research in Ayurvedic Sciences (CCRAS) together with BRIC-NII (the National Institute of Immunology).
• A central scientific aim is to study TB-associated cachexia — the severe wasting of muscle and fat that accompanies tuberculosis — using a battery of modern tools: DEXA scans, MRI, immune profiling, metabolomics and single-cell RNA sequencing.
• Officials placed the effort under a "whole-of-science, whole-of-government, whole-of-nation" framing, signalling that the trial is meant to set a methodological template for testing traditional medicine with rigorous endpoints.

Background & context

Tuberculosis is a bacterial infection caused chiefly by Mycobacterium tuberculosis, most commonly affecting the lungs (pulmonary TB) but capable of attacking almost any organ (extrapulmonary TB). It spreads through the air when an infected person coughs or sneezes. The frontline treatment has long been a fixed multi-drug regimen — the standard ATT built around isoniazid, rifampicin, pyrazinamide and ethambutol, taken under supervision for several months. This study does not touch that backbone. It asks a narrower, carefully bounded question: when a recognised Ayurvedic intervention is added on top of the full ATT course, does the patient recover better — particularly in regaining the body weight and muscle mass that TB strips away?

That framing matters because it places the study in the lineage of India's recent push to put its traditional-medicine claims through standardised clinical evaluation rather than asserting them. The institutional vehicle is the DBT-Ayush MoU of 25 May 2022, which formalised collaboration between the country's biotechnology research arm and its traditional-medicine ministry. The Ayush side is anchored by CCRAS, the apex autonomous body under the Ministry of Ayush for research in Ayurveda; the biotechnology and immunology side is anchored by DBT and BRIC-NII. The choice of marquee hospitals — AIIMS, JIPMER, NEIGRIHMS — signals an intent to run the trial inside mainstream tertiary-care settings, where ATT is already delivered through the NTEP, India's national programme for TB control (the rebranded successor to the older Revised National Tuberculosis Control Programme).

The release situates the new trial alongside two existing Indian TB-research platforms it references for scale: RePORT India (the Regional Prospective Observational Research for Tuberculosis consortium, an India-US collaborative cohort cited at 4,500-plus patients) and an Indian TB genomic-surveillance effort cited at 32,000-plus sequenced strains. These are the data backbones against which a new interventional study can be benchmarked — cohorts for natural-history data, genomic surveillance for tracking drug resistance.

It also helps to be clear about the architecture of the institutions named, because they each play a different role in the design. DBT is the central department for biotechnology research under the Ministry of Science & Technology — it brings funding, molecular-biology capacity and the immunology lens. BRIC-NII refers to the National Institute of Immunology, now part of the DBT's restructured network of research institutes, contributing the immune-profiling and single-cell work. CCRAS is the apex autonomous research council under the Ministry of Ayush and supplies the Ayurvedic intervention and its standardisation. The hospitals — AIIMS (the apex public tertiary-care and teaching institutes), JIPMER (the institute of national importance at Puducherry) and NEIGRIHMS (the North Eastern Indira Gandhi Regional Institute of Health and Medical Sciences at Shillong) — are the clinical sites where patients are enrolled and ATT is delivered. Spreading sites across regions, including the North-East, is also a way to capture geographic and genetic diversity in the patient population. The whole arrangement is what the government means by "whole-of-government": a department of science, a ministry of traditional medicine, autonomous research councils and national hospitals working a single protocol.

For Prelims

• Name: Clinical Study on Ayurveda as an Adjunct to Anti-Tuberculosis Treatment (ATT) — announced 24 March 2026.
• Who runs it: A joint DBT (Ministry of Science & Technology) + Ministry of Ayush initiative; rooted in a DBT-Ayush MoU of 25 May 2022; led by CCRAS with BRIC-NII.
• Design: A ~24-month study enrolling about 1,250 newly diagnosed TB patients across eight institutions — including AIIMS, JIPMER, NEIGRIHMS — conducted under the National TB Elimination Programme (NTEP).
• Scientific focus: TB-associated cachexia (disease-driven wasting), probed with DEXA, MRI, immune profiling, metabolomics and single-cell RNA sequencing.
• Reference platforms: RePORT India (4,500+ patients) and India's genomic surveillance effort (32,000+ strains).
• TB burden: India carries roughly 25% of the global TB burden; incidence about 187 per 100,000 in 2024, a roughly 21% fall since 2015.
• World TB Day: Observed on 24 March, marking the day in 1882 when Robert Koch announced his discovery of Mycobacterium tuberculosis, the bacterium that causes TB.
• CCRAS: The apex autonomous research council under the Ministry of Ayush for Ayurvedic research — the Ayurveda counterpart to the CSIR/ICMR-style research bodies in modern science.

What it is NOT: This is not a proposal to replace anti-TB drugs with Ayurveda, and not an endorsement of Ayurveda as a standalone TB cure. The whole premise is the word adjunct — Ayurveda is added on top of the full standard ATT regimen, which every enrolled patient continues to receive. It is also not a vaccine trial and not a drug-resistance study; its primary lens is recovery and wasting (cachexia), not the development of a new antibiotic. And it is distinct from the surveillance/cohort platforms (RePORT India, genomic surveillance) it cites — those supply context, while this is a fresh interventional study.

The set it belongs to (don't confuse them): Several TB-related items recur in current affairs and are easily mixed up. NTEP is the national control programme (with the political target of TB elimination). World TB Day is the awareness day on 24 March. The WHO Global TB Report is the annual international assessment that supplies global-burden figures. Ni-kshay is India's digital TB patient-management portal and Ni-kshay Mitra the community-support initiative for nutritional aid to patients. BCG is the long-standing TB vaccine. This 2026 study sits apart from all of these as a research trial on an Ayurvedic add-on. Keeping that ladder straight — day vs programme vs report vs portal vs vaccine vs this trial — is what "how many of these are correctly matched" questions test.

Why it matters

India's TB problem is enormous in absolute terms: carrying about a quarter of the world's cases, the country is the single largest contributor to the global disease burden, which is why national policy has set an ambitious elimination goal well ahead of global timelines. The cited fall in incidence — to about 187 per 100,000 in 2024, down roughly 21% from 2015 — shows real progress, but the remaining burden is large and the human cost of TB extends well beyond the infection itself. One of the most debilitating features is cachexia: patients lose weight, muscle and strength, which slows recovery, weakens immune response and worsens outcomes even when the bacteria are being killed by drugs. Standard ATT treats the infection but does little directly for this wasting.

That gap is the opening this study targets. By rigorously testing whether an Ayurvedic intervention, added to ATT, helps patients regain body mass and recover faster, the trial aims to address a real clinical weakness in TB care using a tradition that has long emphasised restoring strength and nutrition (the Ayurvedic concept of rasayana, or rejuvenation). The deeper significance is methodological: by running the test inside mainstream hospitals, under the national programme, with hard biological readouts (DEXA, MRI, metabolomics, single-cell sequencing), it tries to move claims about traditional medicine from assertion to evidence. If the design holds, it offers a replicable template for evaluating other Ayush interventions — which is exactly the bridge between modern science and traditional knowledge that the government's "integrative medicine" push has been seeking.

For Mains

Related: Ayush & integrative medicine · Science & Tech · This week's cards